Education
About Us
Working with TipRanks
Follow Us
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (AU:IMR)
ASX:IMR
Total Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has a market cap or net worth of AU$603.38M. The enterprise value is AU$338.61M.
Market CapAU$603.38M
Enterprise ValueAU$338.61M
Share Statistics
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has 320,947,020 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding320,947,020
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s return on equity (ROE) is -2.27 and return on invested capital (ROIC) is -58.27%.
Return on Equity (ROE)-2.27
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-58.27%
Return on Capital Employed (ROCE)-0.83
Revenue Per Employee10.00T>
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover<0.01
Inventory Turnover2.19
Valuation Ratios
The current PE Ratio of Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is ―. Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh’s PEG ratio is 0.36.
PE Ratio―
PS Ratio1042.05
PB Ratio27.34
Price to Fair Value27.34
Price to FCF-15.61
Price to Operating Cash Flow-29.63
PEG Ratio0.36
Income Statement
In the last 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh had revenue of 302.50K and earned -26.20M in profits. Earnings per share was -0.09.
Revenue302.50K
Gross Profit-2.10M
Operating Income-23.59M
Pretax Income-26.20M
Net Income-26.20M
EBITDA-22.56M
Earnings Per Share (EPS)-0.09
Cash Flow
In the last 12 months, operating cash flow was -14.40M and capital expenditures -311.64K, giving a free cash flow of -14.71M billion.
Operating Cash Flow-14.40M
Free Cash Flow-14.71M
Free Cash Flow per Share-0.05
Dividends & Yields
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.11
52-Week Price Change33.33%
50-Day Moving Average1.95
200-Day Moving Average1.56
Relative Strength Index (RSI)42.77
Average Volume (3m)287.54K
Important Dates
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh upcoming earnings date is Sep 1, 2026, After Close (Confirmed).
Last Earnings DateFeb 24, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh as a current ratio of 2.47, with Debt / Equity ratio of 230.83%
Current Ratio2.47
Quick Ratio2.41
Debt to Market Cap0.08
Net Debt to EBITDA-0.31
Interest Coverage Ratio-5.47K
Taxes
In the past 12 months, Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh EV to EBITDA ratio is -14.29, with an EV/FCF ratio of -15.96.
EV to Sales1.07K
EV to EBITDA-14.29
EV to Free Cash Flow-15.96
EV to Operating Cash Flow-16.32
Balance Sheet
Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has AU$40.81M in cash and marketable securities with AU$26.62M in debt, giving a net cash position of AU$14.19M billion.
Cash & Marketable SecuritiesAU$40.81M
Total DebtAU$26.62M
Net CashAU$14.19M
Net Cash Per ShareAU$0.04
Tangible Book Value Per ShareAU$0.04
Margins
Gross margin is -895.69%, with operating margin of -7796.89%, and net profit margin of -8661.59%.
Gross Margin-895.69%
Operating Margin-7796.89%
Pretax Margin-8661.59%
Net Profit Margin-8661.59%
EBITDA Margin-7456.40%
EBIT Margin-7796.89%
Analyst Forecast
The average price target for Imricor Medical Systems, Inc. Shs Chess Depository Interests Repr 1 Sh is AU$2.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetAU$2.61
Price Target Upside58.94% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast-8.99%
EPS Growth Forecast-18.16%